SCHEDULE 13G: Adage Capital Management Discloses 9.04% Stake in Cidara Therapeutics

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a 9.04% beneficial ownership stake in Cidara Therapeutics, Inc. as of March 31, 2025.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 990,000 shares of Cidara Therapeutics, Inc. Common Stock.
• This stake represents 9.04% of the company's outstanding Common Stock.
• The percentage is calculated based on 10,953,490 shares of Common Stock outstanding as of February 27, 2025, as reported in Cidara Therapeutics' Form 10-K for the fiscal year ended December 31, 2024.
• The reporting persons share both voting and dispositive power over all 990,000 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cidara Therapeutics.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Cidara Therapeutics is a biotechnology company. The disclosure of a significant stake by an investment manager like Adage Capital Management is a common occurrence in the biotech sector, where institutional investment plays a crucial role in funding research and development and can signal investor confidence.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may be viewed by other shareholders as a vote of confidence, although the filing itself does not explicitly state this.
• Company Management: Awareness of a large institutional holder may influence strategic decisions or communication, but the filing explicitly states the stake is not for control.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Adage Capital Management, Robert Atchinson, Phillip Gross, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Biotechnology, Pharmaceuticals